A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
A phase 3 trial of Giredestrant and Docetaxel in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) is a phase 3 interventional study registered as NCT05296798 by Hoffmann-La Roche, with 922 participants enrolled, started 2022-07-18 and due to reach its primary completion in 2027-10-31. Interventions recorded: Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist and Optional Endocrine Therapy of Investigator's Choice.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
Shares Giredestrant, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Shares Giredestrant, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Shares Giredestrant, Flatiron Health (Roche) and the tag pipeline.
- TrialA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Shares Giredestrant, Flatiron Health (Roche) and the tag pipeline.
- TrialA Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Shares Flatiron Health (Roche), Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Shares Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Shares Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.